- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- ABBV-927, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 1,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
- Interventions
- Binimetinib, Brigatinib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Lung Cancer (NSCLC)
- Interventions
- JBI-802, Pembrolizumab
- Drug
- Lead sponsor
- The Christ Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Interventions
- CHS-006 (anti-TIGIT), toripalimab (anti-PD-1)
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Detroit, Michigan • Reno, Nevada + 1 more
- Conditions
- Neoplasms
- Interventions
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 3
- States / cities
- Miami, Florida • Tampa, Florida • Houston, Texas
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer, RCC, Clear Cell Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer), Endometrial Cancer
- Interventions
- ADU-1805, Pembrolizumab
- Drug
- Lead sponsor
- Sairopa B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • St Louis, Missouri • Canton, Ohio + 1 more
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Cemiplimab, Computed Tomography, Dexamethasone, Docetaxel, Magnetic Resonance Imaging, Ramucirumab
- Procedure · Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 413
- States / cities
- Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 335 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Drug
- Lead sponsor
- Clovis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 31
- States / cities
- Bakersfield, California • Duarte, California • Fullerton, California + 27 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Taxoprexin, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- pemetrexed, nivolumab, paclitaxel, veliparib, carboplatin
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Whittier, California • Aurora, Colorado + 3 more
- Conditions
- Melanoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer
- Interventions
- HBI-8000 in combination with nivolumab
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • La Jolla, California • Port Saint Lucie, Florida + 3 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sutetinib Maleate Capsule
- Drug
- Lead sponsor
- Teligene US
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 6
- States / cities
- Glendale, California • Athens, Georgia • Louisville, Kentucky + 3 more
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Breast Cancer, Ovarian Cancer, Cervical Cancer, Endocervical Cancer, Colorectal Cancer, Esophageal Cancer
- Interventions
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Newport Beach, California • Santa Monica, California + 15 more
- Conditions
- Advanced Non-small Cell Lung Cancer
- Interventions
- RO5126766
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Miami, Florida • New York, New York • Allentown, Pennsylvania
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more
- Conditions
- Lung Cancer, Pneumonitis, Radiation-Induced Lung Injury, Immunotherapy-Induced Pneumonitis, Non-Small-Cell Lung Cancer (NSCLC)
- Interventions
- incentive spirometry
- Device
- Lead sponsor
- The Cooper Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Lung Cancer
- Interventions
- Carboplatin, Pemetrexed, Bevacizumab, Cixutumumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Amivantamab, Osimertinib, Lazertinib, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,074 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 20
- States / cities
- Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
- Conditions
- Cancer
- Interventions
- counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
- Other · Procedure
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • White River Junction, Vermont
- Conditions
- Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
- Interventions
- Avelumab, Axitinib, Palbociclib
- Drug
- Lead sponsor
- Worldwide Innovative Network Association
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- La Jolla, California • Sioux Falls, South Dakota
- Conditions
- Solid Tumors
- Interventions
- DF6002, Nivolumab
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 21
- States / cities
- Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- eribulin mesylate
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Duarte, California • Pittsburgh, Pennsylvania
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- Pemetrexed, Carboplatin
- Drug
- Lead sponsor
- Instituto Nacional de Cancer, Brazil
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Miami Beach, Florida
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- CP-751,871, paclitaxel, carboplatin, erlotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more